Dual biologics for severe asthma and atopic dermatitis: Synopsis of two cases and literature review

The efficacy and safety of the combination of biologic therapies remain unclear with an ineffective and insufficient single biologic for managing asthma. Herein, we report two cases using dual biologics for severe asthma and atopic dermatitis. A 52‐year‐old male patient who received dupilumab and mepolizumab, benralizumab, or tezepelumab, followed by bronchial thermoplasty, and a 41‐year‐old male patient who received dupilumab and omalizumab, both experienced improved asthma and atopic dermatitis. To date, 38 cases are using dual biologics for severe asthma. The success rate was 84%, with no major adverse effects. We report the first case of severe asthma receiving dual biologics with tezepelumab and furthermore bronchial thermoplasty, and comprehensive literature review on dual biologics. Dual biologics may be an effective treatment method for severe asthma, requiring further investigation. Herein, we report two cases using dual biologics for severe asthma and atopic dermatitis. A 52‐year‐old male patient who received dupilumab and mepolizumab, benralizumab, or tezepelumab, followed by bronchial thermoplasty, and a 41‐year‐old male patient who received dupilumab and omalizumab, both experienced improved asthma and atopic dermatitis. Dual biologics may be an effective treatment method for severe asthma, requiring further investigation.